The purpose of this study was to compare the effects of the preoperative use of crystalloids, colloids, tranexamic acid and epsilon-aminocaproic acid on bleeding in gynecologic cancer surgery. Materials and Methods: 105 ASA I-II patients undergoing gynecologic cancer surgery were included in the study. Group I (crystalloid) were given crystalloid solutions, Group II (colloid) were given colloid solutions, Group III (Tranexamic acid) were given 10 mg/kg tranexamic acid, and Group IV (epsilonaminocaproic acid) were given 100 mg/kg epsilon-aminocaproic acid. All patients' bleeding amount were measured and recorded perioperatively, and at the 12th and 24th hours postoperatively. All patients' hemoglobin, hematocrit, aPTT, INR, fibrinogen, and thrombocyte count and symptoms of pulmonary embolism were evaluated preoperatively and at the 12th and 24th hours postoperatively. One-Way analysis of variance, Duncan test and Kruskal-Wallis variance analysis were used to compare the variables in the four groups. Time related variables were analyzed using paired t-test and Wilcoxon test. The differences in variables related to time and coagulation values were analyzed with Chi square and Kappa tests. p Ͻ 0.05 were considered as significant.
Background and Goal of Study: Hyperglycemia during cardiac procedures and cardiopulmonary bypass (CPB) may be severe. 1 The etiology of the disturbance of the plasma glucose-insulin relationship includes inadequate insulin secretion and decreased endogenous insulin activity. It has been postulated that aprotinin may increase the biological effectiveness of insulin by the inhibition of insulin degradation or by decreasing insulin resistance. 2 This putative effect of aprotinin, however, has not been evaluated in cardiac surgical patients. Materials and Methods: A systematic review of an existing database of cardiac surgery patients at a major U.S. tertiary care medical center was performed. Patients selected met all of the following criteria: the use of CPB, preoperative serum creatinine р1.2 mg/dl, no history of diabetes mellitus, no perioperative insulin or steroid therapy. Patients were then divided into 3 groups; no aprotinin (control), full dose aprotinin (FDA) or half dose aprotinin (HDA). Glucose levels were obtained at predetermined intervals. Results and Discussions: 96 patients met all of the criteria. Of these, 61 received aprotinin (FDA ϭ 28, HDA ϭ 33) and 35 did not. The only significant demographic difference between the groups was fewer reoperations in the control group. The FDA group had significantly lower plasma glucose levels than both the control group and HDA group. (Fig 1. 
Conclusion(s):
In this study, patients receiving aprotinin were found to have significantly lower glucose levels when administered full-dose compared to control and to the half-dose regimen. Further study is warranted to evaluate the clinical relevance of this finding. References: 
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Tranexamic acid reduces blood loss in knee arthroplasty E. Vela, J.C. Alvarez, X. Santiveri, I. Gonzalez, I. Ramos, S. Pacreu, L.l. Aguilera
Department of Anesthesiology, H. del Mar. IMAS, Barcelona, Spain
Background and Goal of Study: Total knee arthroplasty is carried out by using tourniquet, which enhances certain fibrinolytic effect, specially during the first postoperative hours. Tranexamic acid (TKA), antifibrinolytic agent, reduces blood loss in total knee arthroplasty 1 , but its effect in continuous infusion during the immediate postoperative period has never been tested in this kind of surgery.
The objective of our study was to evaluate the effect of TKA on blood loss and its influence in the transfusional needs. Method: Double blind prospective study. Patients scheduled for total knee arthroplasty were randomly assigned to two different groups. Group TKA: 30 minutes before the tourniquet liberation, a 10 mg/kg bolus of TKA was given, and a 1 mg/kg/h perfusion was started for 6 hours. Group control: SSF was given in the same manner. Blood loss (expressed with drainage volume and total calculated bleeding at fourth day -ml of red blood cell units, hematocrit 100%), allogenic or autologous transfusion, and complications were registered. 
Conclusion:
Tranexamic acid use before the release of tourniquet and in perfusion during 6 hours after the surgery of knee arthroplasty, reduce the drainage blood loss and the total calculated bleeding at fourth day significantly. Allogenic transfusion index is reduced too, but not signficantly in our study.
Reference:
1 Hippala ST, et al. Tranexamic acid radically decreases blood and transfusions associated with total knee arthroplasty. Anest. Analg. 1997; 84: 839-44 .
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Factor VII administration attenuates deleterious consequences of consumptive coagulopathy following amniotic fluid embolism
Department of Anesthesiology, Assaf Harofeh Medical Center, Zerifin, Israel
Background and Goal of Study: Amniotic fluid embolism (AFE) is a deleterious, often lethal, pregnancy complication. In as much as 83% of cases, AFE is followed by consumptive coagulopathy, manifested by persistent massive bleeding. During delivery, the management of the latter includes transfusion of large quantities of whole blood and blood components, frequently followed by surgical intervention. We propose a simple method, attenuating the severity of labor-associated, AFE-induced bleeding, and reducing the quantities of blood/blood component transfusions.
Materials and Methods:
A 40-year-old female was admitted to the labor ward at the 42nd week of her 12th pregnancy. After 2 h of labor, at full dilatation of the cervix, she suddenly developed typical AFE. She was immediately treated for cardiac complications, and finally the fetus was successfully delivered by forceps extraction. Several minutes after delivery, a severe postpartum hemorrhage and bleeding from the vein puncture sites started, urging immediate laparotomic hysterectomy. The hemorrhage persisted, despite oxytocin administration and massive blood/blood component replacement. At this point, the patient was administered two successive doses of recombinant activated factor VII (Novoseven), 7.4 mg and 3.7 mg, respectively. Results: The hemorrhage stopped, the patient's hemodynamics, coagulation and metabolic parameters became stable. By the end of laparotomy, 5.5 h' after the initial collapse, she was transferred to the Intensive Care Unit.
Conclusions:
We suggest that repetitive administration of factor VII at the early stages of AFE might significantly attenuate the severity of AFE-induced bleeding during delivery. In addition, the timely use of factor VII would significantly reduce the massive quantity of blood/blood component replacement needed, thus proving cost-effective and, at least in some cases, prevent surgical intervention, i.e. hysterectomy, in still young and fertile female patients.
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Additional aspirin effectively shortens bleeding time prolonged by daily low-dose aspirin Background and Goal of Study: Discontinuation of anti-platelet drugs several days before surgery increases the risk of ischemic events. Conversely, patients on low-dose aspirin treatment risk of excessive bleeding during emergency surgery. Our preliminary report found that additional 660 mg of aspirin shortens bleeding time prolonged by low-dose aspirin (1). The purpose of the present study was to verify this effect in additional subjects in comparison with a placebo group. Materials and Methods: Subjects comprised 50 healthy male volunteers (mean age, 24 Ϯ 3 years) who were administered aspirin 81 mg every morning for 7 days. On day 7, Group A (n ϭ 25) received aspirin 660 mg, and Group C (n ϭ 25) received placebo. Bleeding time, maximum platelet aggregation rate induced by adenosine diphosphate (ADP) or collagen, platelet count, prothrombin time (PT), and activated partial thromboplastin time (APTT) were measured before the study (baseline), and before and 2 h after test drug administration. Results and Discussion: Bleeding time was significantly prolonged after aspirin 81 mg administration for 7 days, from 3.1 Ϯ 0.7 min to 6.1 Ϯ 1.4 min in Group A (P Ͻ 0.01), and from 2.9 Ϯ 0.9 min to 6.1 Ϯ 1.5 min in Group C (P Ͻ 0.01). Additional aspirin decreased bleeding time to 4.5 Ϯ 1.3 min (P Ͻ 0.01) in Group A, while bleeding time was unchanged in Group C. Platelet count decreased significantly from 25.2 Ϯ 5.7 ϫ 10 4 mm Ϫ3 to 19.5 Ϯ 2.5 ϫ 10 4 mm Ϫ3 for a week in Group A, but PT and APTT showed no significant changes. Maximum platelet aggregation rate induced by collagen was significantly decreased, and that induced by ADP also tended to decrease in both groups. Conclusion: Incremental administration of 660 mg of aspirin could shorten bleeding times prolonged by daily low-dose aspirin.
Reference:
1 Yokoyama T, Yamashita K, Yamasaki F, et al. Masui. 2003; 52: 399-401 .
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Additional aspirin shortens bleeding time in patients taking daily low-dose aspirin, but prolongs it in patients treated with ticlopidine T. Yokoyama, F. Yamasaki, K. Yamashita, S. Yagi, R. Kiyooka, A. Imoto, M. Manabe
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Background and Goal of Study: Ticlopidine and low-dose aspirin are often used as anti-platelet drugs. Both drugs are usually discontinued several days before surgery to avoid excessive bleeding during surgery. During emergency surgery, the risk of excessive bleeding has to be considered. Whether additional high doses of aspirin offset the bleeding tendency resulting from low-dose aspirin administration is known as the Aspirin Dilemma (1). The present study investigated the effects of additional aspirin on bleeding time in patients taking ticlopidine or aspirin in comparison with placebo groups. Materials and Methods: Subjects comprised 41 patients, with 20 patients (13 men; mean age, 67 Ϯ 7 years) on ticlopidine 200 mg/day (Group T), and 21 patients (12 men; mean age, 70 Ϯ 12 years) on low-dose aspirin 81 mg/day (Group A). 12 of group T and 14 of group A took aspirin 660 mg, and others took placebo immediately after measuring bleeding time, capillary fragility test and platelet count. Values were measured again 2 h later. Results and Discussions: Bleeding time was prolonged significantly from 5.1 Ϯ 3.1 min to 9.9 Ϯ 4.2 min after 660 mg of aspirin in Group T (P Ͻ 0.01). In Group A bleeding time was shortened significantly from 7.3 Ϯ 3.1 min to 3.4 Ϯ 1.6 min (P Ͻ 0.01). However, there was no significant difference in patients administered placebo in both groups. No significant differences in capillary fragility test or platelet count were noted between groups, either before or after administration of additional aspirin or placebo.
Conclusion(s):
Administration of an additional 660 mg of aspirin prolongs bleeding time in patients taking daily ticlopidine, but shortens bleeding time in patients taking daily low-dose aspirin. Additional aspirin may be useful in patients taking low-dose aspirin to help prevent hemorrhaging during emergency operation. Conversely, aspirin should be used carefully for analgesia in patients taking ticlopidine. Reference: 1 Marcus AJ. NEJM. 1977; 297: 1284 -1285 .
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Background: Aspirin is widely used for prevention cardio-and cerebrovascular complications. Recommendations to stop aspirin intake before surgery are based on platelet life span and vary between 7 to 10 days. Although evidence of platelet function recovery is lacking, it has been suggested that less than 7 days are required (1). The goal of this study was to detect the time of recovery of platelet function after cessation of aspirin therapy. Methods: After IRB approval and signed informed consent 12 healthy male volunteers were enrolled in the study. Aspirin effect on platelets was evaluated by aggregometry activated by arachidonic acid (ARA), epinephrine (EPN), and adenosine diphosphate (ADP). Aggregometry was performed before aspirin administration, on the 10th day of aspirin intake, on the 1st, 2nd, 3rd, 4th, and 7th days after aspirin cessation. The data was analyzed with ANOVA for repeated measurements and presented as mean Ϯ SD, p Ͻ 0.05 is considered significant. Results and Discussion: Platelet aggregation with ARA and EPN decreased significantly after aspirin intake. Aggregation with ADP remained unchanged during all period of the observation. Aggregation with ARA and EPN returned to normal value on the 3rd day after aspirin cessation (Table) . Background and Goal of Study: Thromboelastogram (TEG) is regarded as a method by which coagulation can be measured during surgery. Off pump coronary artery bypass (OPCAB) surgical patients are routinely placed on aspirin. But conventional TEG could not detect platelet dysfunction by antiplatelet agent (1). We used modified TEG (addition of heparin and platelet agonists) to determine whether this modified TEG could assess the platelet dysfunction by aspirin in OPCAB surgical patients and healthy volunteers (2). Materials and Methods: After institutional review board approval and consent, platelet function of 10 OPCAB patients (group 1) and 10 healthy
